RTTNews | Dec 24, 2021 05:56AM EST

05:55 Friday, December 24, 2021 (RTTNews.com) - Novavax Inc. (NVAX) and SK bioscience Co. Limited, a vaccine business subsidiary of Korea-based SK Group, said that they expanded their collaboration and license agreements for NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine.

Novavax secured additional manufacturing capacity through 2022. SK bioscience secured long-term license to supply NVX-CoV2373 for the Korean market.

Additionally, SK bioscience has acquired non-exclusive rights to sell doses of Novavax' vaccine to the governments of Thailand and Vietnam.

Read the original article on RTTNews ( https://www.rttnews.com/3251469/sk-bioscience-secures-long-term-license-to-supply-nvx-cov2373-for-korean-market.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved